{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-23-000055","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2023-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.673059+00:00","generated_at":"2026-06-14T00:15:25.466601+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Stockholders approve amended stock purchase plan adding 125,000 shares at 2023 annual meeting","bullets":["All three Class II director nominees (David Arthur, Bruce McCreedy, Jonathan Lieber) elected with over 267,000 votes each.","Amended ESPP approved: reserve increased by 125,000 shares, with annual automatic increase (2% or 75k shares) through 2028.","Non-binding advisory vote on executive compensation approved with 216,044 for, 85,774 against.","Ratification of Ernst & Young as auditor for FY2023 approved with 913,353 for."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-23-000055","json":"https://secwatch.observer/filing/0001615219-23-000055.json","markdown":"https://secwatch.observer/filing/0001615219-23-000055.md","text":"https://secwatch.observer/filing/0001615219-23-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521923000055/0001615219-23-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521923000055/flks-20230614.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:15:25.466601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b1fb04511c394a3b0b8701daddbcbefe6ca404c","claim":"Decoy Therapeutics Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-06-14 meeting.","evidence_excerpt":"3. Proposal to provide a non-binding advisory vote on the compensation of the Company’s named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 216,044 85,774 12,655 727,170","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1615219/000161521923000055/0001615219-23-000055-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"31bc6c3850ab0d79317d05e2d3db0992a0f0a552","claim":"Decoy Therapeutics Inc. shareholders approved Election of three Class II directors at the 2023-06-14 meeting.","evidence_excerpt":"1. Proposal to elect three Class II directors to serve until the 2026 annual meeting or until their successors are duly elected and qualified: Nominees Votes For Votes Against Abstentions Broker Non-Votes David J. Arthur 270,248 632 43,593 727,170 Bruce J. McCreedy 267,578 641 46,254 727,170 Jonathan Lieber 269,684 547 44,242 727,170","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1615219/000161521923000055/0001615219-23-000055-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"54a93a5d50c3361b9d19fd011f3dd0893caa86ec","claim":"Decoy Therapeutics Inc. shareholders approved Approval of Amended and Restated Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan at the 2023-06-14 meeting.","evidence_excerpt":"2. Proposal to approve the Amended and Restated Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan: Votes For Votes Against Abstentions Broker Non-Votes 224,289 74,630 15,554 727,170","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1615219/000161521923000055/0001615219-23-000055-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"93706ebef9881e52019925821f1b0c52d8a281ea","claim":"Decoy Therapeutics Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-06-14 meeting.","evidence_excerpt":"4. Proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Votes For Votes Against Abstentions 913,353 103,072 25,218","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1615219/000161521923000055/0001615219-23-000055-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}